• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Amgen shares fall after Q2 earnings reveal ‘bare’ pipeline

July 26, 2017 By Sarah Faulkner

AmgenShares in Amgen (NSDQ:AMGN) fell today even though the biotech topped expectations on Wall Street with its second quarter results.

The Thousand Oaks, Calif.-based company posted profits of $2.2 million, or $2.91 per share, on sales of $5.8 billion for the 3 months ended June 30, for bottom-line growth of 15% on sales growth of 2% compared with the same period last year.

Adjusted to exclude 1-time items, earnings per share were $3.27, ahead of consensus on The Street, where analysts were looking for sales of $5.67 billion.

“Our continued solid performance this quarter is yet another indication that we are on track to deliver on our long-term growth objectives,” chairman & CEO Robert Bradway said in prepared remarks. “Our newer products are registering strong volume-driven growth globally and we expect their contribution to continue to increase over time, offsetting declines in mature products.”

Leerink Partners analyst Geoffrey Porges reportedly noted that although some of Amgen’s drugs did well this quarter, the company doesn’t seem prepared to “offset the flattening legacy products.”

“The company requires new opportunities to offset the further decline of legacy products, and their late stage pipeline looks embarrassingly bare,” Porges wrote, according to CNBC.

Amgen said it expects to post adjusted EPS of $12.15 to $12.65 apiece on sales of $22.5 billion to $23 billion for the full year.

AMGN shares were trading at $175.69 apiece today in afternoon activity, down -2.9%.

Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.

Filed Under: Featured, MassDevice Earnings Roundup, Pharmaceuticals, Wall Street Beat Tagged With: Amgen

IN CASE YOU MISSED IT

  • Insulet hires new chief HR officer from J&J
  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS